In a regulatory filing, Crinetics Pharmaceuticals president and CEO Richard Scott Struthers disclosed the sale of 50,000 common shares of the company on June 16 at a price of $20.81 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRNX:
- Crinetics presents efficacy, safety, outcome of ENDO 2023
- 3 Best Stocks to Buy Now, 6/21/2023, According to Top Analysts
- Crinetics participates in a conference call hosted by H. C. Hainwright
- Crinetics announces inducement grants under Nasdaq listing rule
- Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)